Myeloproliferative Neoplasms (MPN)

- CNL/atypical CML:
  - IRB# 10262: Oral Ruxolitinib for CNL or atypical CML.

- Myelofibrosis:
  - IRB# 16363: Phase 2 INC8050465 plus Ruxolitinib.
  - IRB# 15836: Dual Syk/Jak inhibitor for myelofibrosis with JAK2 mutation.

- Systemic Mastocytosis:
  - IRB# 17899: Study Coming Soon.

- IRB# 15977: Non Treatment National MDS Study (ECOG/ACRIN)

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php